Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Classes of recommendations
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Levels of evidence
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Investigational algorithm for patients with coronary artery disease and diabetes
mellitus
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Definition, classification, and screening of diabetes
and pre-diabetic glucose abnormalities
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Criteria used for glucometabolic classification according
to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose)
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Aetiological classification of glycaemia disordersaa
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Conversion factors between plasma and other vehicles for glucose values
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Fasting and post-load glucose levels identify
different individuals with asymptomatic diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults
Task
Forc
e o
n D
iabete
s and C
VD
(ESC
and E
ASD
) Euro
pean H
eart
Journ
al
20
07
;28
:88
-13
6
Epidemiology of diabetes, IGH, and cardiovascular risk
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in
the DECODE study
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Identification of subjects at high risk for CVD or diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Summary of the findings of four lifestyle intervention studies
that aimed at preventing type 2 diabetes in subjects with IGT
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment to reduce cardiovascular riskLifestyle and comprehensive management
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Mean efficacy of pharmacological treatment options in patients with type 2 diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Percentage of patients achieving pre-defined
intensive treatment targets in the Steno 2 study
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Glycaemic targets for the care of patients with
diabetes as recommended by various organizations
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Potential downsides of pharmacological treatment modalities in patients with type 2
diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Suggested policy for the selection of glucose-lowering therapy according to the
glucometabolic situation
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment to reduce cardiovascular risk - Dyslipidaemia
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients
with and without diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment to reduce cardiovascular risk - Blood pressure
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment effects of antihypertensive drugs in
comparison with placebo or less intensive treatment as reported in randomized
clinical trials
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different
antihypertensive treatments in hypertensive patients with type 2 diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Management of CVD - Coronary artery disease
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Treatment options based on accumulated evidence
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Recommended treatment targets for patients with diabetes and CAD
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Diabetes and coronary revascularization
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Trials addressing diabetes and revascularization
for multivessel disease
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Revascularization in diabetes patients with multivessel disease in the stent-era
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Heart failure and diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Arrhythmias: atrial fibrillation and sudden cardiac death
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Peripheral vascular disease
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Investigations of the peripheral circulation in diabetic patients
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Stroke
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Intensive care
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Published trials on intensive insulin therapy in critical illness
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Health economics and diabetes
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Direct medical costs for patients with type 2 diabetes
in eight European countries and percentage of healthcare expenditure in the respective
countries (1998)
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136